Inkemia, through its new platform, is able to get new Drug Discovery compounds in a more efficient and flexible way than other companies.

Such platform is capable of designing, synthetizing and evaluating candidate molecules to interact with pharmacological targets.

We have the work teams, the infrastructure, know-how and a wide experience in:

-        Design and chemistry synthesis.

-        Medicinal chemistry.

-        High Throughput Experimentation.

-        High Throughput Analysis.

-        Structural elucidation and

-        Intellectual Property search.

More over, our team has a lot of experience in:

-        Organic synthesis, biotechnology and biocatalysis processes through the use of proprietary enzymes or with live microorganisms.

-        Computational chemistry tools for “in silico” design of candidates.

-        Specific know-how on scale up process for the afterwards production of industrial products.

Among our activities you can choose between: the design and modification of scaffolds, “de novo” structure design, the design of routes of scaffolds and libraries, the synthesis of scaffolds and building blocks, transformation of multi step processes to one-pot reactions, highly chemical, region and stereo selective processes, low cost developments, exclusive processes...and many others.

As a summary, Inkemia offer you:

-        Flexibility: up to complementary 4 ways of synthesis of compounds.

-        Added value: we not only provide you the desired compounds but as well the whole synthesis pathway for a further pilot or industrial scale up.

-        We can produce any type of native, recombinant or mutant enzyme.

-        Wide experience and background in analysis and synthesis.

We also have a wide collection of molecules and hits in cancer and other diseases (viral, inflammation, coagulation, etc.) available for its licensing o Codevelopment Agreements.

1)              Chemical library of new nucleoside analogues for tests of anticancer activity: through the HTB platform, IUCT has a powerful technological tool to design libraries of hundreds of new nucleoside analogues through the synergy of coupling biotechnological and organic synthesis tools.

There are currently about 500 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

 Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new anticancer drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Delivery and scale-up: it is possible to re-synthesize or to scale the products up to 1-2 g.

We also have hits available for its licensing or for Codevelopment Agreements in several cancer indications: lung, breast, colon, liver, prostate, kidney, pancreas, lymphoma, leukaemia and glioblastoma.

2)              Chemical library of new nucleoside analogues for tests of antiviral activity: through the HTB platform, IUCT owns a powerful technological tool to construct libraries of new nucleoside analogues through the synergy of coupling biotechnologic and organic synthesis tools

There are currently about 500 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new antiviral drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Delivery and scale-up: it is possible to re-synthesize or to scale the products up to 1-2 g.

3)          Chemical libraries of novel sulphonamides as antagonists of receptors involved in inflammatoryprocesses: the compounds have been designed as antagonists of Bradykinin B₁ and B₂ receptors that mediate pain and inflammation, involved in inflammatory processes like: respiratory diseases (asthma, rinitis), arthritis, pancreatitis, sepsis, etc.

There are currently about 200 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for most of the molecules in the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits o lead compounds in the R&D of new anti-inflammatory drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Robust synthetic schemes: it is possible to re-synthesize or to scale-up the products according to the development stage.

4)              Chemical libraries of novel sulphonamides for anticoagulation tests: the compounds have been designed as inhibitors of several proteins involved in the coagulation process: Thrombine (Factor FIIa), Activated Factor X (FXa), Coagulation Factor VIIa, Trypsin, Coagulation Factor IX, etc.

There are currently about 200 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Structural novelty for the majority of the molecules of the collection.

-        Compounds fulfilling drug requirements (drug-like structures).

-        Possibility of identifying hits or lead compounds in the R&D of new anticoagulant drugs.

-        Possibility of identifying hits in the R&D of new pharmacological activities.

-        Robust synthetic schemes: it is possible to re-synthesize or to scale-up the products according to the development stage.

5)              Library of tropanic compounds: library of tropanic compounds with activity on the Central Nervous System (CNS). 

There are currently about 30 molecules of which we provide information about its structure, purity, concentration and its full technical sheet in ChemFinder format.

All the compounds can be served individually, as subgroup (according to the customer’s needs) or as library or global collection.

Additionally, it is possible to prepare focused scaffolds based on structural requirements of the customer.

Advantages

-        Possibility of identifying hits orlead compounds in the R&D of new compounds in the aforementioned indications from derived compounds of a structure with activity in this field.

-        Very complex synthesis optimized.

We also have 3 hits that have shown an improvement in the motor activity in a flies’ model with Parkinson Disease, available for its licensing or Codevelopment Agreements. If you want more

The EPS are macromolecules ofcarbohydrates, that often are together with proteines, and are synthetized by bacterial enzymes and secreted and acummulated out of the cell giving to the culture a mucilaginous aspect.

The main carbohydrates are the following monosaccharides:

-         Rhamnose: 28-45%

-         Glucosamine: 12-20%

-         Glucose: 20-30%

-         Galactose: 15-25%

Inkemia obtain the EPS from halophile bacteria, bacteria that grow in very high salt concentrations like salt mines. Inkemia has optimized the purification, the culture and the production processes at lab scale, and we are prepared for its production at industrial scale through simple processes like ultrafiltration and lyophilization.

The EPS are shown like a podwer of different colors, usually white, and water soluble.

Inkemia have a collection of almost 100 different compounds, most of them identified or being identified regarding its composition and properties. Some EPS have shown to have properties that make them useful as active ingredients in cosmetics or for the pharmacological treatment of some diseases.

They can be used, as well, as nutraceuticals (food supplement of a concentrated biactive sustance that is supposed to have a benefitial effect on the human health).

Among the EPS of Inkemia fully developed and available for its immediate licensing, we have the compounds C2 and C3.

C2: it has a powerful antioxidant activity, demonstrated according to FDA guidelines, through a double mechanism of action. The studies, carried out in human keratinocytes, have shown that C2 has a GSH/GSSG ratio 15 times bigger than control at 1 µg/ml concentration.

At the same time C2 stimulates the endogen synthesis of keratin (+40% vs. control in keratinocyte cells). As a result, hair appearance (health, strength and resistance) was improved through an unique mechanism of action. There is no other product in the market that stimulates the endogenous synthesis of keratin.

Both applications, its potent antioxidant activity and the stimulation of the endogenous keratin synthesis, make of C2 a very good choice for the hair care cosmetic formulations.

C3:it hasa good antioxidant activity and has shown an excellent protection against the DNA damage produced by UV radiation (60% less thymine dimmers compared with control).

Both applications, its potent antioxidant activity and the protection against the DNA damage produced by UV radiation, make of C3 an excellent active ingredient for the skin care and sun care cosmetic formulations.

There are other EPS still in development like:

-        A36: in in vitro studies it has shown to increase the collagen synthesis and to have a protective effect against the oxidation induced by UV radiation. We are currently carrying out additional efficacy studies in other applications as well as in vitro safety studies.

-        A05, A16 and A53: in studies in zebra fish embryos they have shown to have a whitening effect, by inhibiting the melatonine production, with a good safety profile. We are doing additional tests.

-        C02: in studies, as well in zebra fish embryos, it has shown to have neuroactive effects without toxicity signs. We are doing additional tests.

-        A16 and C05: they show a protective effect against the oxidation induced by UV radiation. We are currently doing additional efficacy studies in other applications as well as in vitro safety studies.

-        A50 and A53: they have shown to increase the collagen synthesis. It is forecasted to carry out additional efficacy studies in other applications as well as in vitro safety studies.

Inkemia also offer collaboration models, through Codevelopment Agreements, with interested  companies. We put at the disposal of these companies the opportunity to work with our collection of EPS compounds to carry out studies in the applications required by the customer.

In case of success, if there is shown that some or several EPS have positive results, have a good safety profile and are subject of a patent, the Intelectual Property could belong to the customer.

Licensing Out is the Department of IUCT in charge of negotiating the license of products & technologies obtained as a result of its research activity.

IUCT currently holds 70 granted patents in three large fields like:

-        Drug Development,Drug Discovery, Biomedicine.

-        Industrial Biotechnology and Biofuels.

-        Green Chemistry and Green Products.

Some of these patents come from products/technologies in which all the researches are finished and available for its license or technology transfer. Among them we have:

Exopolysaccharides (EPS):new active ingredients for the cosmetic industry.

-        C2: it has shown a potent antioxidant activity (it increases 15 times the GSH/GSSG ratio) and it notably stimulates the endogen keratin synthesis (more than 40% compared to control). Due to their properties, it is specially indicated for the formulation of hair care products like shampoos, hair conditioners….

-        C3: it has an excellent antioxidant activity, scavenging and detoxifying the cells from the free radicals, and it is also capable of counteracting the malignat effects of UV radiation (up to 60% more when compared to control). These properties makes C3 specifically indicated for its use in skin, anti-aging and sun protection formulations.

Drug Discovery libraries:we have a variable number of compounds already synthetized for their use in the research of new drugs in areas like:

-        Cancer: lung, breast, colon, liver, pancreas, kidney, lymphoma, leukaemia and glyoblastoma

-        Viral diseases: AIDS, HIV, hepatitis…

-        Central Nervous System diseases: Alzheimer, Parkinson, anxiety disorders, depression…

-        Coagulation.

-        Inflammatory diseases.

We have also obtained some hits, compounds that have shown in vitro activity, in the aforementioned areas. Such hits are available for licensing or for Co-development agreements with interested companies.

Drug Discovery services:it includes the design, synthesis and evaluation of candidate molecules to interact with pharmacological targets. Our team has:

-        Infrastructure: with the latest techniques of chemistry synthesis, medicinal chemistry, high throughput analysis, high throughput experimentation, structural elucidation and intellectual property search.

-        Wide experience.

-        Know-how: organic synthesis, biotechnology and biocatalysis processes through the use of proprietary enzymes or with live microorganisms.

Inkemia offers:

Flexibility: up to complementary 4 ways of synthesis of compounds.

      Added value: we not only provide you the desired compounds but as well the whole synthesis pathway for a further pilot or industrial scale up.

      We can produce any type of native, recombinant or mutant enzyme.

      Wide experience and background in analysis and synthesis.

The Licensing Out Department also carry out Co-development Agreements with other companies by providing the compounds obtained in its research and cooperating with some expenses and/or tests, and the other companies carry out the in vitro/in vivo efficacy and safety tests with such compounds. 

In case of success, the Intellectual Property and any income from the licensing as well as the the expenses done until the product had been licensed are shared 50% by each party.

We are a dynamic, flexible and creative team in the search of solutions for our customers,  as well as a market oriented company

Biofuels:

-        S50: the first new advanced biofuel economically viable of Europe obtained from crude glycerol or any source of triglycerides like vegetable oils, used cooking oils, animal fats, etc.

-        Bioheating oil: it is a fuel for boilers in production processes that demand a big amount of energy like those of cement, asphalt, distilleries, chemical companies, etc. It notably improves the air quality when compared with traditional fossil fuels like fuel oil.

-        Glycerol to FAME (biodiesel) technology: we have developed a technology that allow the biodiesel producers to increase its profitability through the transformation of crude glycerol, a very low added value by-product obtained in the biodiesel production, into biodiesel, a biofuel of common use in the road transport.